DNDI-6174 is a cytochrome bc1 complex inhibitor with potent in vitro activity against a variety of Leishmania species. DNDI-6174 can reduce parasite burden in animal models of infection.
References:
[1]. Stéphanie Braillard, et al. DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1. Sci Transl Med. 2023 Dec 13;15(726):eadh9902.
















